INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/007531

A CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/435 A61K38/17 A61P3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} & \mbox{A61P} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included. In the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, PASCAL

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	_
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SHRIDHAR V ET AL: "Mutations in the arginine-rich protein gene (ARP) in pancreatic cancer." ONCOGENE. 8 MAY 1997, vol. 14, no. 18, 8 May 1997 (1997-05-08), pages 2213-2216, XP001204720 ISSN: 0950-9232 cited in the application the whole document	1-36
X	WO 02/074956 A (PRESCIENT NEUROPHARMA INC ; COMMISSIONG JOHN W (CA); RAIBEKAS ANDREI A) 26 September 2002 (2002-09-26) cited in the application	1-18, 26-29,36
Υ	claims 1-36 page 6, line 9 - line 25	1-36

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed	"T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
4 January 2005	2 & 04. 2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018	Authorized officer Fayos, C

INT NATIONAL SEARCH REPORT

Internal Application No
PCT/EP2004/007531

		PC1/EP2004/00/531
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/19851 A (NEUROTROPHIC BIOSCIENCE INC; RAIBEKAS ANDREI A (CA); COMMISSIONG JOHN) 22 March 2001 (2001-03-22) cited in the application	1-18, 26-29,36 1-36
Y	claims 1-33	1-30
X Y Y	US 2002/132978 A1 (GERBER HANS-PETER ET AL) 19 September 2002 (2002-09-19) cited in the application claims 1-61	1-18, 21-24, 26-29,36 1-36
X	WO 02/079246 A (BOUGUELERET LYDIE ;	1-18,23,
Υ	NIKNEJAD ANNE (CH); BAIROCH AMOS (CH); GENEPROT IN) 10 October 2002 (2002-10-10) claims 1-34	24, 26-29,36 1-36
1		

INTERNATIONAL SEARCH REPORT

International application No. PCT/EP2004/007531

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-36 (partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-36 (partially)

A pharmaceutical composition comprising DG153; the use of DG153 for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases; a non-human transgenic animal or recombinant host cell exhibiting a modified expression of DG153; use of DG153 in an identification / screening method.

2. claims: 1-36 (partially)

A pharmaceutical composition comprising DG177; the use of DG177 for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases; a non-human transgenic animal or recombinant host cell exhibiting a modified expression of DG177; use of DG177 in an identification / screening method.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interconal Application No PCT/EP2004/007531

Patent document cited in search report	Publication date		
WO 02074956 A	26-09-2002	WO 02074956 A2 CA 2441740 A1 EP 1373502 A2 JP 2004528835 T US 2002182198 A1	26-09-2002 26-09-2002 02-01-2004 24-09-2004 05-12-2002
WO 0119851 A	22-03-2001	AU 7263300 A WO 0119851 A2 CA 2383076 A1 EP 1220681 A2 JP 2003511352 T	17-04-2001 22-03-2001 22-03-2001 10-07-2002 25-03-2003
US 2002132978 A	1 19-09-2002	US 2004006780 A1 AU 5091201 A CA 2403804 A1 EP 1290005 A2 JP 2004501608 T WO 0170174 A2	08-01-2004 03-10-2001 27-09-2001 12-03-2003 22-01-2004 27-09-2001
WO 02079246	10-10-2002	CA 2441327 A1 WO 02079246 A2 EP 1373314 A2	10-10-2002 10-10-2002 02-01-2004